Publications by authors named "V Gnemmi"
Background & Aims: The aim of this study was to investigate the consequences of the histological progression of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis on long-term survival after bariatric surgery.
Methods: From 1994 to 2021, 3028 patients at the University Hospital of Lille were prospectively included. Baseline liver biopsies were systematically performed with proposed follow-up biopsies 1 year after surgery, mainly in patients with MASH.
Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits considerable variability in clinical outcomes. Identifying specific phenotypic profiles within MASLD is essential for developing targeted therapeutic strategies. Here we investigated the heterogeneity of MASLD using partitioning around medoids clustering based on six simple clinical variables in a cohort of 1,389 individuals living with obesity.
View Article and Find Full Text PDFBackground: Although hepatic production of FGF23 has been suggested in chronic settings, there are no data indicating hypophosphatemia resulting from acute hepatic FGF23 production. Based on two clinical observations of profound hypophosphatemia in the setting of acute hepatitis, our study investigates the hypothesis of acute FGF23 liver expression.
Methods: Retrospective analyses were conducted to estimate FGF23 liver expression both qualitatively ( hybridization) and quantitatively (relative FGF23 gene expression and protein production) on histological specimens of human and murine acute hepatitis livers, compared with controls of hepatic fibrosis or healthy liver.
Article Synopsis
- - C5-blockers are currently the recommended treatment for complement-mediated hemolytic uremic syndrome (CM-HUS), but lack definitive testing often leads to plasma exchanges as the first treatment, despite limited evidence.
- - A study involving 7 patients treated without plasmapheresis showed that administering a C5-blocker called eculizumab promptly led to rapid hematological recovery and improved renal function for most patients.
- - The promising results suggest the need for further clinical trials to confirm this approach's effectiveness and safety while also addressing the high costs associated with C5-blocker therapies for broader use in adults with renal thrombotic microangiopathy (TMA).
Key Points: We evidenced terminal pathway activation (C5b-9 deposits) in most of the glomeruli on kidney biopsy of C3 glomerulopathy. The amount of C5b-9 deposits correlated with disease prognosis in C3 glomerulopathy. Increased terminal pathway activation was found predominantly in a subgroup exhibiting an immuno-fibroblastic signature.
View Article and Find Full Text PDF